Tissue Factor Pathway Inhibitor (Tfpi) – An Update

Sandset, Per Morten

doi:10.1159/000217293

Cited by 54 publications

(64 citation statements)

References 38 publications

(54 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Tissue factor is inhibited by a specific inhibitor, tissue factor pathway inhibitor (TFPI), synthesized and expressed by endothelial cells in the microcirculation. 50-80% of TFPI forms the endothelial pool, 10-50% circulates in plasma and less than 2.5% is found in thrombocytes 16 . TFPI prevents excessive thrombin formation by binding to activated factor X in the TF/FVIIa/FXa complex 17,18 .…”

Section: Tissue Factor -Biological Functionsmentioning

confidence: 99%

The role of tissue factor in normal pregnancy and in the development of preeclampsia: A review

Procházková¹,

Slavík²,

Úlehlová³

et al. 2015

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub

View full text Add to dashboard Cite

Background. Tissue factor (TF) is a key element for normal gestation, especially in the first trimester. TF levels are hence raised in pregnancy, producing an adaptive hypercoagulable state. Potentiated hypercoagulability however, is associated with disorders of pregnancy such as pre-eclampsia but the results of TF and its inhibitor, tissue factor pathway inhibitor (TFPI), measurement, in pre eclampsic women are ambiguous and the data conflicting. This review covers the current knowledge status of the role of TF assessment in pregnancy with a focus on its diagnostic utility. Methods. A review of the literature using the following key words: tissue factor, thrombosis, inflammation, pregnancy, preeclampsia.Results. The published literature shows raised and unchanged TF levels in various studies of pre-eclampsia along with equally conflicting data for TFPI. The various study designs and methods used in these studies makes valid comparison difficult. Meta analysis of 34 randomized trials showed that low-dose aspirin in early phases of gravidity (starting from the 16th week or earlier) significantly reduces the incidence of preeclampsia. Conclusions. Overall, the results of the literature search together with knowledge of the structure and biological effects of TF, suggest that measuring the level of plasma TF/TFPI is not ideal for determining the actual levels of TF in the uteroplacental circulation. The current view that endothelial dysfunction is the trigger for preeclampsia, suggests that aspirin may be an effective prophylaxis. Further research will be necessary: measuring the expression of tissue factor on monocytes using flowcytometry and comparing the development of this expression during normal pregnancy and pregnancy complicated by preeclampsia, for example. Another possibility is immunohistochemical determination of the level of TF expression directly in placental tissue.

show abstract

Section: Tissue Factor -Biological Functionsmentioning

confidence: 99%

The role of tissue factor in normal pregnancy and in the development of preeclampsia: A review

Procházková¹,

Slavík²,

Úlehlová³

et al. 2015

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub

View full text Add to dashboard Cite

show abstract

“…15,16 In experimental models, TFPI plays a critical regulatory role in controlling the effects of tissue factor. Mice deficient in the TFPI gene died in utero owing to intrauterine coagulopathy and vascular disintegrity.…”

Section: Introductionmentioning

confidence: 99%

Low levels of tissue factor pathway inhibitor (TFPI) increase the risk of venous thrombosis

Dahm

Vlieg

Bendz

et al. 2003

Blood

Self Cite

226

208

View full text Add to dashboard Cite

There is now strong experimental evidence that tissue factor pathway inhibitor (TFPI) is a critical inhibitor to modulate tissue factor-induced coagulation, but the role of TFPI as a risk factor for thrombosis is yet to be to be determined. This study investigated the role of low TFPI levels for the development of deep-vein thrombosis (DVT). We determined TFPI activity and TFPI-free and total antigen levels in the subjects enrolled in the Leiden Thrombophilia Study, which is a large population-based case-control study of 474 patients and 474 controls. The odds ratio (OR) for DVT in subjects who had TFPI-free antigen levels below the 10th percentile, as compared with those who had TFPI-free antigen levels above this cutoff, was 1.7 (95% confidence interval [CI], 1.1-2.6). The ORs for low TFPI activity and low total antigen were also mildly increased. When the 5th percentile was used as a cutoff, the ORs were 2.1 (95% CI, 1.1-4.1) for both TFPI-free antigen and TFPI total antigen. Exogenous female hormones had a profound lowering effect on TFPI levels, with lower levels in oral contraceptive users than in premenopausal nonusers, who had lower levels than men and postmenopausal women. These results indicate that low levels of TFPI, especially low TFPI-free and total antigen in plasma, constitute a risk factor for DVT.

show abstract

“…2 Intravascular TFPI exists in several pools. 3 The free form of TFPI in plasma (f-TFPI) generally reflects the level of endothelial cell-associated TFPI and displays a potent anticoagulant activity, whereas lipid-bound TFPI seems to have only a small or no anticoagulant function. 4 -6 TM is an endothelial cell-surface receptor for thrombin that functions as an anticoagulant by greatly accelerating thrombin-induced activation of protein C. 7 A soluble truncated form of TM (sTM) circulates in plasma; until now, its physiological role has been unknown.…”

mentioning

confidence: 99%

Endothelial Cell Markers and the Risk of Coronary Heart Disease

et al. 2004

View full text Add to dashboard Cite

on behalf of the PRIME Study Group Background-Tissue factor pathway inhibitor (TFPI), von Willebrand factor (vWF), and thrombomodulin (TM) are 3 major hemostatic regulatory molecules synthesized by endothelium. Data from epidemiological studies aiming to evaluate the relation between plasma levels of these molecules and the development of coronary heart disease (CHD) are sparse or contradictory. Methods and Results-We examined the association between these endothelial-cell markers and the incidence of fatal or nonfatal myocardial infarction (hard CHD) and stable or unstable angina (angina pectoris) in a prospective cohort (the PRIME Study) of nearly 10 000 healthy men recruited in France and Northern Ireland. We measured baseline plasma concentration of the free form of TFPI (f-TFPI), vWF, and the soluble form of TM (sTM) among 296 participants who subsequently developed CHD over the 5-year follow-up (158 with hard CHD and 142 with angina pectoris) and in 563 control subjects by use of a nested case-control design. Individuals with plasma vWF levels in the highest quartile showed a 3.04-fold increase in the risk of hard CHD compared with those in the lowest quartile (95% CI, 1.59 to 5.80). Individuals with f-TFPI levels below the 10th percentile had a 2.13-fold increased risk of hard CHD compared with those with levels above it (95% CI, 1.08 to 4.18). The risk for both molecules persisted after control for inflammatory parameters. Individuals with vWF levels in the highest quartile and f-TFPI levels below the 10th percentile presented a 6.9-fold increased risk of hard CHD compared with those with vWF levels in the lowest quartile and f-TFPI levels above the 10th percentile (95% CI, 1.3 to 37.8). Conclusions-vWF and f-TFPI plasma levels were independent risk factors for hard CHD events.

show abstract

Tissue Factor Pathway Inhibitor (Tfpi) – An Update

Cited by 54 publications

References 38 publications

The role of tissue factor in normal pregnancy and in the development of preeclampsia: A review

The role of tissue factor in normal pregnancy and in the development of preeclampsia: A review

Low levels of tissue factor pathway inhibitor (TFPI) increase the risk of venous thrombosis

Endothelial Cell Markers and the Risk of Coronary Heart Disease

Contact Info

Product

Resources

About